Literature DB >> 21835501

Longitudinal epidemiology of multidrug-resistant (MDR) Acinetobacter species in a tertiary care hospital.

Ji Hoon Baang1, Peter Axelrod, Brooke K Decker, Andrea M Hujer, Georgia Dash, Allan R Truant, Robert A Bonomo, Thomas Fekete.   

Abstract

BACKGROUND: Acinetobacter species are well-known causes of health care-associated infections. The longitudinal epidemiology of this species in the hospital setting is poorly understood. A sudden, persistent increase in multidrug-resistant (MDR) A baumannii infections occurred beginning in June 2006 at Temple University Hospital in Philadelphia. An analysis was done to describe the longitudinal molecular epidemiology of MDR A baumannii in a tertiary care hospital.
METHODS: This was an epidemiologic investigation using repetitive extragenic palindromic-PCR (rep-PCR) of patients with a positive culture for MDR A baumannii admitted to the hospital between February 2006 and January 2010. MDR A baumannii were defined as susceptible only to colistin and/or tigecycline.
RESULTS: The incidence rate of MDR A baumannii rose from 0.36 cases per 1,000 patient-days (pre-epidemic) to 0.86 cases per 1,000 patient-days, due mainly to an increase in the surgical intensive care unit. Enhanced infection control measures were implemented, but waves of MDR A baumannii continued to be documented through routine surveillance. Of 32 strains collected in 2006-2007, a single predominant clone and 2 minor clones accounted for almost all of the cases of MDR A baumannii studied. Of 24 strains collected in 2008-2009, another clone, different from those studied in the earlier period, predominated, and was accompanied by 3 minor variants.
CONCLUSION: Following an outbreak in the surgical intensive care unit, MDR A baumannii persisted in our institution for a 3-year period despite rigorous infection control measures. An unexpected strain replacement occurred during this period, with the original predominant strain disappearing completely and new minor clones displacing the original minor clones. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835501      PMCID: PMC4086168          DOI: 10.1016/j.ajic.2011.04.326

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  19 in total

1.  Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection.

Authors:  M del Mar Tomas; M Cartelle; S Pertega; A Beceiro; P Llinares; D Canle; F Molina; R Villanueva; J M Cisneros; G Bou
Journal:  Clin Microbiol Infect       Date:  2005-07       Impact factor: 8.067

Review 2.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  The sequences of seven class D beta-lactamases isolated from carbapenem-resistant Acinetobacter baumannii from four continents.

Authors:  S Brown; S G B Amyes
Journal:  Clin Microbiol Infect       Date:  2005-04       Impact factor: 8.067

4.  Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study.

Authors:  J L García-Garmendia; C Ortiz-Leyba; J Garnacho-Montero; F J Jiménez-Jiménez; C Pérez-Paredes; A E Barrero-Almodóvar; M Gili-Miner
Journal:  Clin Infect Dis       Date:  2001-08-22       Impact factor: 9.079

5.  Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes.

Authors:  D M Sengstock; R Thyagarajan; J Apalara; A Mira; T Chopra; K S Kaye
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

6.  Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System.

Authors:  L C McDonald; S N Banerjee; W R Jarvis
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

7.  An outbreak of Acinetobacter baumannii: the importance of cross-transmission.

Authors:  E M D'Agata; V Thayer; W Schaffner
Journal:  Infect Control Hosp Epidemiol       Date:  2000-09       Impact factor: 3.254

8.  Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii.

Authors:  X Corbella; A Montero; M Pujol; M A Domínguez; J Ayats; M J Argerich; F Garrigosa; J Ariza; F Gudiol
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

9.  Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility.

Authors:  H Wisplinghoff; M B Edmond; M A Pfaller; R N Jones; R P Wenzel; H Seifert
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

10.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

View more
  9 in total

1.  Whole-Genome Sequencing Elucidates Epidemiology of Nosocomial Clusters of Acinetobacter baumannii.

Authors:  Stefanie Willems; Stefanie Kampmeier; Stefan Bletz; Annelene Kossow; Robin Köck; Frank Kipp; Alexander Mellmann
Journal:  J Clin Microbiol       Date:  2016-06-29       Impact factor: 5.948

2.  Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway.

Authors:  Timothy R Sampson; Xiang Liu; Max R Schroeder; Colleen S Kraft; Eileen M Burd; David S Weiss
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

3.  Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Authors:  Krisztina M Papp-Wallace; Baui Senkfor; Julian Gatta; Weirui Chai; Magdalena A Taracila; Veerabahu Shanmugasundaram; Seungil Han; Richard P Zaniewski; Brian M Lacey; Andrew P Tomaras; Marion J Skalweit; Michael E Harris; Louis B Rice; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

4.  In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections.

Authors:  Ling Wang; Yong-Jun Wang; Yin-Yin Liu; Hui Li; Ling-Xia Guo; Zhong-Hua Liu; Xiao-Liu Shi; Min Hu
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

5.  Endemic Acinetobacter baumannii in a New York hospital.

Authors:  Scott A Weisenberg; Audrey N Schuetz; Elizabeth L Alexander; Elizabeth A Alexander; Brain Eiss; Maryam Behta; Lisa Saiman; Davise H Larone; Stephen G Jenkins; Kyu Y Rhee
Journal:  PLoS One       Date:  2011-12-13       Impact factor: 3.240

6.  Molecular characterisation and control of Acinetobacter baumannii isolates resistant to multi-drugs emerging in inter-intensive care units.

Authors:  Ayşe Ertürk; Ayşegül Çopur Çiçek; Aziz Gümüş; Erkan Cüre; Ahmet Şen; Aysel Kurt; Alper Karagöz; Nebahat Aydoğan; Cemal Sandallı; Rıza Durmaz
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-07-22       Impact factor: 3.944

7.  Carbapenem-resistant Acinetobacter baumannii from Serbia: revision of CarO classification.

Authors:  Katarina Novovic; Sanja Mihajlovic; Zorica Vasiljevic; Brankica Filipic; Jelena Begovic; Branko Jovcic
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

8.  Multi-locus sequence typing (MLST) of non-fermentative Gram-negative bacilli isolated from bloodstream infections in southern Poland.

Authors:  Agnieszka Chmielarczyk; Monika Pobiega; Dorota Romaniszyn; Jadwiga Wójkowska-Mach
Journal:  Folia Microbiol (Praha)       Date:  2017-09-22       Impact factor: 2.099

9.  Faucet aerators as a reservoir for Carbapenem-resistant Acinetobacter baumannii: a healthcare-associated infection outbreak in a neurosurgical intensive care unit.

Authors:  Qian Xiang; Ying Z Jin; Yu Lv; Ying Fang; Yu J Wu; Bin Zeng; Hua Yu; Hong M Cai; Qiong D Wei; Chen Wang; Jing Chen; Hui Wang
Journal:  Antimicrob Resist Infect Control       Date:  2019-12-30       Impact factor: 4.887

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.